Carisbamate

N/A

Report date: 2022/03/23 13:26:24
NME

Base Information

Drug NameCarisbamate
Drug Alias NameComfyde卡立氨酯CarisbamatoCarisbamatumYKP-509 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurotransmitter receptor modulators
TargetsNeurotransmitter receptor
Therapy Area/IndicationsNeuralgia, PostherpeticNeuralgiaDiabetic Neuropathies +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaIND
Originator CompaniesSK Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInsignis Therapeutics IncSK Biopharmaceuticals Co LtdXian Janssen Pharmaceutical Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSeizuresLennox Gastaut Syndrome
Inactive IndicationsNeuralgia, PostherpeticNeuralgiaDiabetic Neuropathies +[10] 

Other Information

ATC CodeN03AX19
Related LinksWikipediaDrugBankKEGG